Recombinant Human Tumor Protein 63 (TP63) Protein (His)

Name: Recombinant Human Tumor Protein 63 (TP63) Protein (His)
Brand: Beta LifeScience
SKU: BLC-03567P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Tumor Protein 63 (TP63) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q9H3D4
Target Symbol	TP63
Synonyms	AIS; Amplified in squamous cell carcinoma ; B(p51A); B(p51B); Chronic ulcerative stomatitis protein; CUSP; DN p63 alpha 1; DNp63; EEC3; id:ibd3516; Keratinocyte transcription factor ; Keratinocyte transcription factor KET; KET; LMS; MGC115972; MGC192897; NBP; OFC8; OTTHUMP00000209732; OTTHUMP00000209733; OTTHUMP00000209734; OTTHUMP00000209735; OTTHUMP00000209737; OTTHUMP00000209738; OTTHUMP00000209739; OTTHUMP00000209740; OTTHUMP00000209741; OTTHUMP00000209742; OTTHUMP00000209743; OTTHUMP00000209744; p40; p51; P51/P63; p53-related protein p63; p53CP; p63; P63_HUMAN; p73H; p73L; RHS; SHFM4; TAp63alpha; TP53CP; TP53L; TP63; TP73L; Transformation related protein 63; Transformation-related protein 63; Trp53rp1; Trp63; Tumor protein 63; Tumor protein p53-competing protein ; Tumor protein p53-like ; Tumor protein p63; Tumor protein p63 deltaN isoform delta; Tumor protein p73; Tumor protein p73-like
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	MNFETSRCATLQYCPDPYIQRFVETPAHFSWKESYYRSTMSQSTQTNEFLSPEVFQHIWDFLEQPICSVQPIDLNFVDEPSEDGATNKIEISMDCIRMQDSDLSDPMWPQYTNLGLLNSMDQQIQNGSSSTSPYNTDHAQNSVTAPSPYAQPSSTFDALSPSPAIPSNTDYPGPHSFDVSFQQSSTAKSATWTYSTELKKLYCQIAKTCPIQIKVMTPPPQGAVIRAMPVYKKAEHVTEVVKRCPNHELSREFNEGQIAPPSHLIRVEGNSHAQYVEDPITGRQSVLVPYEPPQVGTEFTTVLYNFMCNSSCVGGMNRRPILIIVTLETRDGQVLGRRCFEARICACPGRDRKADEDSIRKQQVSDSTKNGDGTKRPFRQNTHGIQMTSIKKRRSPDDELLYLPVRGRETYEMLLKIKESLELMQYLPQHTIETYRQQQQQQHQHLLQKQTSIQSPSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNALTPTTIPDGMGANIPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHEFSSPSHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQQRIKEEGE
Expression Range	1-680aa
Protein Length	Full Length
Mol. Weight	80.8kDa
Research Area	Apoptosis
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter.
Subcellular Location	Nucleus.
Protein Families	P53 family
Database References	HGNC: 15979 OMIM: 103285 KEGG: hsa:8626 STRING: 9606.ENSP00000264731 UniGene: PMID: 30190462 lncRNA RP185F18.6 and DeltaNp63 may be considered unfavorable biomarkers, whereas GSDMD may be a favorable biomarker in colorectal cancer (CRC) ; these markers may prove valuable in the future diagnosis and prognosis of CRC. PMID: 30226619 Data identified an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk. PMID: 29956121 The malignant lesions showed significantly lower values than the benign lesions in the percentage of p63+ clusters, the percentage of p63+ single cells in the clusters, and the number of p63+ single cells in the background. PMID: 30043485 Expression of TAp63, IKKbeta and XBP1s is also increased in livers of obese patients with liver steatosis . PMID: 28480888 p63 may act as either an oncogene or a tumor suppressor gene in different scenarios: TA isoforms of p63 gene are generally tumor-suppressive through repressing cell proliferation, survival and metastasis; DeltaN isoforms, however, may initiate tumorigenesis via promoting cell proliferation and survival. (Review) PMID: 28975366 Low TP63 expression is associated with neoplasms. PMID: 29180475 Studies suggest for dissecting tumor protein p63 (p63)-controlled mechanisms in normal and diseased epidermal development and for developing therapeutic options [Review]. PMID: 29103147 In leukoplakia, increased expression of survivin reflects on the increased expression of ki-67 and p63. PMID: 28346726 Gene-gene interaction between MSX1 and TP63 may influence the risk of nonsyndromic cleft lip with or without cleft palate in Asian populations. PMID: 29341488 High N-terminally truncated isoform of p63 expression is associated with squamous cell carcinogenesis. PMID: 29735662 The rs35592567 polymorphism in TP63 affected the expression of TP63 by interfering with its interaction with miR-140, and could serve as an explanation for the increased risk of Gastric Cancer. PMID: 29763931 The data from this study showed that p63 was a tumor suppressor mainly through regulating PTEN in chondrosarcoma cells. PMID: 29441939 we first demonstrated that upregulation of P63 in the cartilage tissues of osteoarthritis (OA) patients inhibited chondrocyte autophagy thereby contributing to the malignant progression of OA. PMID: 29442026 high DeltaNp63beta expression up-regulates KLK6-PAR2 and down-regulates PAR1, inducing malignant transformation in oral epithelium with stimulating proliferation through ERK signal activation PMID: 29224812 multiple ankyloblepharon-ectodermal defects-cleft lip/palate syndrome-associated p63 mutations, but not those causative of other diseases, lead to thermodynamic protein destabilization, misfolding, and aggregation PMID: 29339502 LINC01503 is increased in squamous cell carcinoma (SCC) cells compared with non-tumor cells. TP63 bound to the super enhancer at the LINC01503 locus activates its transcription which promotes SCC cell proliferation, migration, invasion, and growth of xenograft tumors. PMID: 29454790 we provide evidence that S100A7 also inhibits YAP expression and activity through p65/NFkappaB-mediated repression of DeltaNp63, and S100A7 represses drug-induced apoptosis via inhibition of YAP. PMID: 28923839 DeltaNp63 promotes head and neck squamous cell carcinoma tumorigenesis via regulation of hyaluronic acid metabolism. p63 expression is a negative prognostic factor of HNSCC patient survival. PMID: 29162693 cases illustrate that: there is significant familial variability, including discordant major but concordant minor anomalies in the first ever reported set of molecularly confirmed monozygotic twins with pathogenic variants in TP63. PMID: 29130604 results reveal a critical role for KMT2D in the control of epithelial enhancers and p63 target gene expression. PMID: 29440247 Loss of Nrf2 inhibits deltaNp63 stem cell mobilization, a key event for reconstitution of radiation-injured lung, while promoting a myofibroblast phenotype that is central for fibrosis. PMID: 28870520 PKC-delta played as a protective role in squamous cell carcinomas partly by down-regulating p63, leading to the suppression of squamous cell carcinomas cell proliferation PMID: 28756980 Immunocytochemical staining using cocktail antibody targeting p63/CK14 was useful for the differential diagnosis of FA and DCIS in FNAC of the breast. PMID: 28685877 Authors conclude that TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear. PMID: 28849221 that both major p63 protein isoforms are expressed in triple-negative breast cancers with different tumour characteristics, indicating distinct functional activities of p63 variants in breast cancer PMID: 29484502 p63-DBD is capable of binding to anti-apoptotic BclxL via its DNA binding interface, a feature that has only been shown for p53 so far. PMID: 27225672 The data indicate that EPCR can regulate p63, is associated with highly proliferative keratinocytes, and is a potential human epidermal stem cell marker. PMID: 28480559 miR-124 regulates p63 via iASPP, while p63 targets miR-155 via the modulation of STAT1 expression in colorectal cancer. PMID: 28418858 The number of p63(+) cells is significantly higher in both hyperplastic (1.53-fold, P < 0.0001) and squamous metaplastic (2.02-fold, P < 0.0001) epithelium from nasal polyps than from healthy controls PMID: 27807867 In p53-deficient breast cancers, compensatory mechanism of NFkB repression by p63 and p73 during genotoxic stress could lead to complex effects that would influence all aspects of tumor progression. PMID: 29107083 findings illustrate that DeltaNp63alpha can inhibit the levels of LIF mRNA by direct transcription regulation and decrease LIF mRNA stability by suppressing the expression of Lnc-LIF-AS. An inverse interaction of LIF and DeltaNp63alpha expression was as well validated in clinical samples of cervical cancer, and high level of LIF in cervical cancers was related with poor patient survival. PMID: 28391028 Negative staining for CK5/6 and p63 can be helpful to distinguish Well-differentiated neuroendocrine tumors (WDNETs) from cutaneous adnexal neoplasms. It is important to consider WDNETs in the differential diagnosis of cutaneous adnexal neoplasms as low-grade tumors may be the first sign of aggressive metastatic disease PMID: 28417484 EGFR pathway gene expression analysis indicated that DeltaNp63 alters EGFR-regulated genes involved in cell adhesion, migration, and angiogenesis. Addition of EGF or neutralizing EGFR antibodies demonstrated that EGFR activation is responsible for DeltaNp63-mediated loss of cellular adhesion PMID: 28349272 SNHG1 might play an oncogenic role in SCC through ZEB1 signaling pathway by inhibiting TAp63. PMID: 28415044 This review discusses the evidence of DeltaNp63alpha as a master regulator of epithelial-mesenchymal transition (EMT) components and miRNA, highlighting the need for a deeper understanding of its role in EMT.[review] PMID: 27924063 miR-223-5p overexpression is a putative pathological mechanism of tumor invasion and a promising therapeutic target; both miR-223-5p and p63 may be prognostic factors in vulvar cancer PMID: 27359057 miR-133b plays an important role in the anti-tumor effects of TAp63 in colorectal cancer. PMID: 27894087 Data show that a dominant-negative effect is widely spread within the p53/p63/p73 family as all p53 loss-of-function hotspot mutants and several of the isoforms of p53 and p73 tested exhibit a dominant-negative potential. PMID: 27589690 As a transcriptionally regulated program, urothelial differentiation operates as a heterarchy, wherein GATA3 is able to co-operate with FOXA1 to drive expression of luminal marker genes, but that P63 has potential to transrepress expression of the same genes. PMID: 28282036 the majority of cells within the tumor appears to express predominantly TAp63 isoform. While DeltaNp63 exerts its effects by regulating a PI3K/CD44v6 pathway. PMID: 27494839 These data suggest that TP63 is a novel Lacrimo-auriculo-dento-digital syndrome gene and may also influence corneal thickness and risk for open-angle glaucoma. PMID: 28400699 the strong repression of Np63 by H-RAS and PIK3CA and induction of EMT suggest that this process is critical for mammary tumorigenesis. PMID: 27681615 Study reveals the existence of a functional cross-talk between two distinct post translational modification controlling DeltaNp63alpha protein turnover. The sumoylation and ubiquitylation of DeltaNp63alpha are strongly intertwined, and none of them can efficiently occur if the other is impaired. PMID: 29246538 This study suggests that in patients with CD30+ lymphoproliferative disorders, an aggressive clinical course cannot be defined by the presence of TP63 rearrangements, as was recently shown in systemic ALK negative anaplastic large cell lymphoma. PMID: 27146432 This study revealed the possible association between TP63 and Mullerian duct anomalies and suggested a potential contribution of microRNA-regulated expression of genes in the etiology of Mullerian duct anomalies. PMID: 27798044 the roles of DeltaNp63alpha during corneal wound healing PMID: 29090620 We identified a list of thirty genes repressed by DeltaNp63 in a SETDB1-dependent manner, whose expression is positively correlated to survival of breast cancer patients. These results suggest that p63 and SETDB1 expression, together with the repressed genes, may have diagnostic and prognostic potential PMID: 26840455 Dysregulation of JAM-A via p63/GATA-3 signaling pathway occurs in squamous cell carcinomas of the head and neck. PMID: 27036044 This study investigated the expression of p40 protein in meningiomas and explored its usefulness as prognostic marker in addition to PgR and Ki67. PMID: 27394131

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.